Research
Hormonal
Liraglutide improves insulin sensitivity (measured by HOMA-IR, HOMA2, and Matsuda index) rapidly, within 2 weeks, independent of weight loss.
If you have obesity and prediabetes, liraglutide improves how your body handles insulin within two weeks, even before you lose significant weight. This is a direct drug effect, not just a result of dieting.
GoodSupportsHIGH confidence
Liraglutide improved insulin sensitivity measured by HOMA for insulin resistance (HOMA-IR), the updated HOMA model (HOMA2), and the Matsuda index after 2 weeks, prior to weight loss.
Why this rating
Randomized controlled trial with crossover design and specific antagonist testing.
Source
Weight Loss–Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes
Mona Mashayekhi et al. · Diabetes · 2023
DOI 10.2337/db23-0356
rct · n=88Cited 56×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →